Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs
Identifieur interne : 003262 ( Main/Exploration ); précédent : 003261; suivant : 003263Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs
Auteurs : Harold E. Paulus [États-Unis]Source :
- The American Journal of Medicine [ 0002-9343 ] ; 1988.
English descriptors
- Teeft :
- Abstract form, American journal, Antimalarial, Antimalarial drug, Antimalarial drugs, Antirheumatic, Arthritis, Arthritis rheum, Auranofin, Aurothiomalate, Azathioprine, Chloroquine, Combination dmard therapy, Combination therapy, Comparative study, Comparison dmards, Cyclophosphamide, Dapsone, Dmard, Dmards, Dos, Erythrocyte sedimentation rate, Grip strength, Hydroxychloroquine, Hydroxychloroquine therapy, Hydroxychloroquinetreated patients, Levamisole, Major improvement, Medicine volume, Methotrexate, October, Open trials, Other dmards, Paulus, Placebo, Randomized, Randomized studies, Relative efficacy, Remission, Retrospective chart reviews, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Significant differences, Similar improvement, Sulfasalazine, Suppl, Toxic drugs, Toxicity.
Abstract
Abstract: Available published comparisons of antimalarial drugs with other disease-modifying antirheumatic drugs (DMARDs) are reviewed, as well as reports of combinations of DMARDs, in the treatment of rheumatoid arthritis and juvenile rheumatoid arthritis. These reports suggest that antimalarial drug toxicity is less than that of parenteral gold, D-penicillamine, auranofin, or dapsone. Its efficacy appears to be equal to or slightly less than that of most comparison DMARDs. Combinations of DMARDs with antimalarials are probably used by a substantial proportion of rheumatologists, but the few prospective, double-blind studies with a balanced design show little or no advantage to combination DMARD therapy. Open, nonrandomized studies and preliminary reports suggest that combination therapy may be useful, usually when another DMARD is added to one or more DMARDs to which the patients did not have a satisfactory response. A few large, prospective, double-blind, randomized studies comparing hydroxychloroquine with several other DMARDs and placebo are needed to establish more confidence in the relative efficacy and utility of hydroxychloroquine. Although the rationale for combination DMARD therapy is attractive, additional preliminary studies of the various possible combinations and doses are needed before definitive trials of promising combinations can be justified.
Url:
DOI: 10.1016/0002-9343(88)90362-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000014
- to stream Istex, to step Curation: 000014
- to stream Istex, to step Checkpoint: 002024
- to stream Main, to step Merge: 003333
- to stream Main, to step Curation: 003262
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs</title><author><name sortKey="Paulus, Harold E" sort="Paulus, Harold E" uniqKey="Paulus H" first="Harold E." last="Paulus">Harold E. Paulus</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3858E4A64AB4B03ECA87A1B95A2062981BE249E3</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0002-9343(88)90362-2</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-QWT6MZ3N-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000014</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000014</idno><idno type="wicri:Area/Istex/Curation">000014</idno><idno type="wicri:Area/Istex/Checkpoint">002024</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002024</idno><idno type="wicri:doubleKey">0002-9343:1988:Paulus H:antimalarial:agents:compared</idno><idno type="wicri:Area/Main/Merge">003333</idno><idno type="wicri:Area/Main/Curation">003262</idno><idno type="wicri:Area/Main/Exploration">003262</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs</title><author><name sortKey="Paulus, Harold E" sort="Paulus, Harold E" uniqKey="Paulus H" first="Harold E." last="Paulus">Harold E. Paulus</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, University of California Los Angeles, School of Medicine, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Medicine</title><title level="j" type="abbrev">AJM</title><idno type="ISSN">0002-9343</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">85</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="45">45</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0002-9343</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9343</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abstract form</term><term>American journal</term><term>Antimalarial</term><term>Antimalarial drug</term><term>Antimalarial drugs</term><term>Antirheumatic</term><term>Arthritis</term><term>Arthritis rheum</term><term>Auranofin</term><term>Aurothiomalate</term><term>Azathioprine</term><term>Chloroquine</term><term>Combination dmard therapy</term><term>Combination therapy</term><term>Comparative study</term><term>Comparison dmards</term><term>Cyclophosphamide</term><term>Dapsone</term><term>Dmard</term><term>Dmards</term><term>Dos</term><term>Erythrocyte sedimentation rate</term><term>Grip strength</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine therapy</term><term>Hydroxychloroquinetreated patients</term><term>Levamisole</term><term>Major improvement</term><term>Medicine volume</term><term>Methotrexate</term><term>October</term><term>Open trials</term><term>Other dmards</term><term>Paulus</term><term>Placebo</term><term>Randomized</term><term>Randomized studies</term><term>Relative efficacy</term><term>Remission</term><term>Retrospective chart reviews</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Significant differences</term><term>Similar improvement</term><term>Sulfasalazine</term><term>Suppl</term><term>Toxic drugs</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Available published comparisons of antimalarial drugs with other disease-modifying antirheumatic drugs (DMARDs) are reviewed, as well as reports of combinations of DMARDs, in the treatment of rheumatoid arthritis and juvenile rheumatoid arthritis. These reports suggest that antimalarial drug toxicity is less than that of parenteral gold, D-penicillamine, auranofin, or dapsone. Its efficacy appears to be equal to or slightly less than that of most comparison DMARDs. Combinations of DMARDs with antimalarials are probably used by a substantial proportion of rheumatologists, but the few prospective, double-blind studies with a balanced design show little or no advantage to combination DMARD therapy. Open, nonrandomized studies and preliminary reports suggest that combination therapy may be useful, usually when another DMARD is added to one or more DMARDs to which the patients did not have a satisfactory response. A few large, prospective, double-blind, randomized studies comparing hydroxychloroquine with several other DMARDs and placebo are needed to establish more confidence in the relative efficacy and utility of hydroxychloroquine. Although the rationale for combination DMARD therapy is attractive, additional preliminary studies of the various possible combinations and doses are needed before definitive trials of promising combinations can be justified.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Paulus, Harold E" sort="Paulus, Harold E" uniqKey="Paulus H" first="Harold E." last="Paulus">Harold E. Paulus</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003262 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003262 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3858E4A64AB4B03ECA87A1B95A2062981BE249E3
|texte= Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs
}}
| This area was generated with Dilib version V0.6.33. |  |